Featured Question

Can you please characterize/summarize the safety profiles of the new cholesterol-modifying drugs based on recent clinical trials?

See The Answer

Get the latest
science delivered
to your inbox

Answers in CME updates are
available in YOUR specialty.

Sign-up Now!

Featured Activities

09-17-2015

Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on Appropriate Patient Selection and Nuances of Clinical Use

Course Director
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center,
Temple Health
Philadelphia, Pennsylvania

09-11-2015

Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on the Current State of the Science and Implications for Practice

Course Director
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center,
Temple Health
Philadelphia, Pennsylvania

04-27-2015

New and Emerging Treatment Options for Hypercholesterolemia: Evaluating the Characteristics, Benefits, Limitations, and Potential Roles

Course Director
Peter P. Toth, MD, PhD, FAAFP, FNLA, FICA, FCCP, FAHA, FACC
CGH Medical Center
Sterling, Illinois
University of Illinois
College of Medicine
Peoria, Illinois
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
Johns Hopkins University
School of Medicine
Baltimore, Maryland

03-15-2013

Challenging Cases in Multiple Sclerosis

Course Director
Aaron E. Miller, MD
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, New York